Education
About Us
Working with TipRanks
Follow Us
Amarin Corporation Plc (AMRN)
:AMRN
AMRN Stock Chart & Stats
$20.25
-$0.01(-2.55%)
At close: 4:00 PM EST
$20.25
-$0.01(-2.55%)
Day’s Range― - ―
52-Week Range$7.08 - $20.90
Previous CloseN/A
Volume726.09K
Average Volume (3M)91.78K
Market Cap
$316.13M
Enterprise Value$44.47M
Total Cash (Recent Filing)$286.59M
Total Debt (Recent Filing)$6.73M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Mar 03, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding20,792,685
10 Day Avg. Volume103,188
30 Day Avg. Volume91,775
Financial Highlights & Ratios
PEG Ratio-1.46
Price to Book (P/B)8.20
Price to Sales (P/S)17.44
P/FCF Ratio-128.50
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue0.22
Enterprise Value/Gross Profit0.50
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$10.00Price Target Upside-50.62% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe total revenues included a $25M upfront payment from the Recordati deal, contributing to the overall revenue growth.
Strategic PartnershipsThe Recordati partnership in Europe helps reshape Amarin's business model by transferring commercialization to a seasoned local partner with established cardiovascular infrastructure and expertise.
Bears Say
Competition ChallengesThe longer-term outlook for the US Vascepa business remains conservative given growing pressure from generic competitors.
Market CompetitionInvestors may remain cautious about the commercial business as the US VASCEPA franchise continues to face significant pressure from at least eight generic competitors.
Amarin News
AMRN FAQ
What was Amarin Corporation Plc’s price range in the past 12 months?
Amarin Corporation Plc lowest stock price was $7.08 and its highest was $20.90 in the past 12 months.
What is Amarin Corporation Plc’s market cap?
Amarin Corporation Plc’s market cap is $316.13M.
When is Amarin Corporation Plc’s upcoming earnings report date?
Amarin Corporation Plc’s upcoming earnings report date is Mar 03, 2026 which is in 105 days.
How were Amarin Corporation Plc’s earnings last quarter?
Amarin Corporation Plc released its earnings results on Oct 29, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.41.
Is Amarin Corporation Plc overvalued?
According to Wall Street analysts Amarin Corporation Plc’s price is currently Overvalued.
Does Amarin Corporation Plc pay dividends?
Amarin Corporation Plc does not currently pay dividends.
What is Amarin Corporation Plc’s EPS estimate?
Amarin Corporation Plc’s EPS estimate is 0.03.
How many shares outstanding does Amarin Corporation Plc have?
Amarin Corporation Plc has 20,792,685 shares outstanding.
What happened to Amarin Corporation Plc’s price movement after its last earnings report?
Amarin Corporation Plc reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went down -11.246%.
Which hedge fund is a major shareholder of Amarin Corporation Plc?
Currently, no hedge funds are holding shares in AMRN
Amarin Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (-50.62% Downside)
$10.00 (-50.62% Downside)
Blogger Sentiment
Neutral
AMRN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 28.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.39%
12-Months-Change
Fundamentals
Return on Equity
-17.35%
Trailing 12-Months
Asset Growth
-16.22%
Trailing 12-Months
Company Description
Amarin Corporation Plc
Amarin Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapies to improve cardiovascular health. The company is primarily known for its flagship product, Vascepa, an omega-3 fatty acid drug approved for use in reducing cardiovascular events in patients with elevated triglyceride levels. Amarin operates within the pharmaceutical sector, specifically targeting cardiovascular diseases, and is dedicated to advancing research and development in this area to provide effective and safe treatment options.
AMRN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook due to significant growth in U.S. market sales, successful partnerships, and strategic cost reductions. However, challenges remain with declining Rest of World revenue and ongoing restructuring costs.View all AMRN earnings summariesAMRN Stock 12 Month Forecast
Average Price Target
$10.00
▼(-50.62% Downside)
Technical Analysis
Altimmune
―
Rigel
―
Aldeyra Therapeutics
―
Rocket Pharmaceuticals
―
Corvus Pharmaceuticals
―
Ownership Overview
4.03% Insiders
1.69% Mutual Funds
1.84% Other Institutional Investors
92.19% Public Companies and
Individual Investors